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Abstract: Excessive drooling may complicate the care of children with chronic neurological 
conditions by socially isolating both patients and families and by causing secondary dermatitis 
and infection. Normal control of saliva requires normal integrity of oral structures, normal 
oropharyngeal sensation, and motor functioning, as well as normal cognitive awareness and 
rate of salivary production. Glycopyrrolate is an anticholinergic medication with a quaternary 
structure that recently received Food and Drug Administration approval to treat sialorrhea 
due to neurological problems in children ages 3–16 years. This review summarizes the few 
published studies of safety and efficacy of glycopyrrolate for drooling in children with chronic 
neurological conditions.
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Introduction
The persistence of drooling in children older than age 3 years is abnormal, occurs in a 
wide variety of neurological disorders, and has no standard treatment. The prevalence 
of neurological disorders in children that are associated with severe and chronic 
drooling is difficult to estimate, in part because of a varied clinical spectrum of such 
disorders; the list of these disorders includes severe developmental delay, cerebral 
palsy, autism spectrum disorders, sensory impairments, traumatic brain injuries, 
as well as neurogenetic and metabolic disorders. Persistent and severe drooling is 
socially disabling for patients and families, complicates hygiene care, and causes 
secondary dermatologic and infectious problems. Chronic drooling is a common 
management issue, with reported prevalence rates varying from 10%1 to almost 40%.2 
Most reports focus on children with cerebral palsy but may include patients with 
other neurological disorders. For example, a recent registry study of 1357 children in 
the Northern Ireland cerebral palsy register reported that approximately one in five 
(22%) children aged 5 years with cerebral palsy experienced drooling.3 Because the 
synthetic anticholinergic glycopyrrolate does not easily cross the blood–brain barrier, 
it theoretically may avoid central nervous system side effects and decrease production 
of saliva, thereby improving drooling caused by neurological disorders in children. 
This review summarizes published studies of the safety and efficacy of glycopyrrolate 
used for the treatment of sialorrhea in children.
Saliva production, handling, and function
The viscosity and production of saliva is typically regulated by such extrinsic stimuli 
as vision, smell, and taste and regulated intrinsically by both the sympathetic and Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  parasympathetic nervous system. Whereas stimulation of 
the sympathetic nervous system tends to thicken saliva, 
stimulation of the parasympathetic nervous system tends 
to induce production of less viscous saliva. In addition to 
providing enzymes (α-amylase and lipase) for initiation of 
carbohydrate digestion, saliva fluid and salivary production 
serve several important homeostatic functions including 
maintaining optimal oral lubrication and acid-base balance, 
as well as providing a bacteriostatic and bactericidal function. 
Thus, disruptions in normal saliva production and handling 
can have oral, dermatologic, and infectious sequelae beyond 
the social disability associated with chronic drooling.
Though data is lacking for children, adults normally   produce 
about 1–1.5 L of saliva daily and, with normal oral   sensation and 
reflex swallowing, saliva is swallowed automatically and with-
out difficulty. Disturbances in the parasympathetic pathways 
(including pons and medulla in the brainstem) that control 
excitatory salivary production as well as sensory deficits, 
oropharyngeal motor weakness, cognitive deficits, medications, 
or chronic tracheostomy may disrupt normal production and 
handling of saliva, resulting in chronic and severe drooling. 
Because both intrinsic and extrinsic factors affect saliva 
production and handling, quantization of both salivary pro-
duction and drooling is problematic; studies often use varying 
methods, thus making comparisons between studies difficult. 
Often subjective rating scales that are completed by family and/
or caregivers are used, but many have not undergone rigorous 
validity testing. Estimates of salivary production in children 
are scarce, but Senner et al found that children with cerebral 
palsy have lower salivary production than control (normally 
developing) children,4   suggesting that drooling in children with 
chronic neurological conditions may stem   predominantly from 
issues other than excess saliva production. In spite of these 
observations, a common approach to management of drooling 
is aimed at reducing saliva production.
Glycopyrrolate – pharmacologic 
properties
Glycopyrrolate is a quaternary ammonium structure that com-
petitively inhibits acetylcholine receptors in salivary glands 
and other peripheral tissues. Thus, indirectly, it may decrease 
salivary production. Originally approved for adjunctive use in 
peptic ulcer disease, it has also been used as a preanesthetic 
agent to decrease secretions. Because of its’ quaternary 
structure, glycopyrrolate does not cross the blood–brain barrier 
well, a characteristic that theoretically makes it more tolerable 
in patients with central nervous system impairments. Taken 
orally, the drug has relatively low and variable bioavailability 
and is excreted largely unmetabolized via the kidneys. After 
oral administration, glycopyrrolate half-life is about 3 hours5 
and drug excretion in patients with renal insufficiency is 
  significantly impaired, so dose adjustments in such patients may 
be required.6,7 Until 2010, glycopyrrolate was only available in 
oral tablet form or intravenous solution (Robinul® and Robinul® 
Forte; Shionogi Pharma, Inc, Florham Park, NJ and injectable 
Robinul®; Baxter Healthcare   Corporation,   Deerfield, IL) and 
oral solutions were compounded from the tablets for patients 
who could not swallow pills or needed smaller dosing. Cober 
et al have demonstrated such compounded solutions are stable 
for 90 days when stored at 23°C–25°C.8 However in July 2010, 
the Food and Drug Administration (FDA) approved an oral 
solution of glycopyrrolate (Cuvposa™; Shionogi Pharma, 
Inc) for the treatment of chronic severe drooling in children 
aged 3–16 years, so both oral pill and liquid formulations are 
now available.
Methods
Search strategy
Studies discussed in this review were identified by searching 
English language PubMed citations from 1950 to July 
2011 using keywords “glycopyrrolate” and “drooling” or 
“sialorrhea” or “sialorrhoea.” Results were limited to humans 
aged 0–18 years and referenced articles in search results also 
screened to look for additional clinical trials of glycopyrro-
late. Two unpublished studies in children are described in the 
Cuvposa™ package insert and are discussed in this review 
because so few clinical studies in children are published.
Results
Of  the 10 manuscripts identified, two were excluded as irrelevant 
to this topic (one had a primary focus on parotidectomy,9 the 
other glycopyrrolate for drooling caused by clozapine10) and four 
were review articles. The remaining four articles discussed below 
are listed in Table 1, along with the two unpublished studies 
discussed in the package insert for oral glycopyrrolate solution.7 
Of these four, only one was a double-blind study. Of the two 
unpublished preapproval studies, study methods and results 
were incompletely described in the package insert, but may be 
gleaned from the FDA Review   Summary as noted in Table 1. 
All four published studies allude to or discuss potential problems 
with blinding and known issues with lack of uniform assess-
ment tools and subjectivity of assessment tools. However, such 
quantitative measures of sialorrhea as measuring weight of saliva 
absorbed into cotton dental pads are not easily accomplished 
and do not measure patients’ physical discomfort or social 
embarrassment.1 Blasco and Stansbury suggest that subjectivity Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 1 Summary of clinical trials that investigated efficacy and safety of glycopyrrolate in children with drooling
Reference Study  
design
Subjects Dose range Duration Outcome measure(s)
Blasco and 
Stansbury15
Open-label,  
dose-ranging
40 children and young 
adults (4–27 years,  
mean 12.5 years)
0.01–0.082 mg/kg/day,  
median 0.09 mg/kg/day,  
split into 1–5 times daily
8 months–4 years Change in drooling quantity  
(“better, worse, same”) and 
side effects
Stern16 Open-label 24 children (3–23 years,  
mean 13.4 years) and 
young adults with 
moderate to profuse 
drooling
0.04–0.1 mg/kg/day  
with maximum of  
0.175 mg/kg/day, given  
as once daily dose
Up to 28 months Questionnaire and drooling 
scale of Thomas-Stonell and 
Greenberg21
Bachrach et al13 Open-label, 
retrospective
37 patients with  
cerebral palsy  
(9 months–  
20 years, mean  
8.3 ± 4.8)
0.01–0.04 mg/kg/dose,  
“most commonly”  
given tid (ie, 0.03– 
0.12 mg/kg/day)
1–34 months 5-point rating scale of  
Camp-Bruno22 and side effects 
(Teacher Drooling Scale)
Mier et al19 Double-blind,  
dose-ranging
39 children  
(4.33–19 years,  
mean 10.75 years) 
mixed neurological 
disorders, mostly  
cerebral palsy
0.04 mg/kg/dose to  
0.2 mg/kg/dose, mean  
0.22 mg/kg/dose in tid 
dosing 
Subjects ,30 kg: 0.6 mg, 
increasing each week  
up to 2.4 mg,  
split into tid dosing 
Subjects .30 kg: 1.2 mg, 
increasing each week  
up to 3.0 mg,  
split into tid dosing
8 weeks placebo or 
glycopyrrolate, 1 week 
washout then 8 weeks  
in reciprocal treatment
Parental/caregiver and 
investigator evaluation of 
change in sialorrhea on 9-point 
drooling scale, modified Teacher 
Drooling Scale (0 = never drools 
to 9 = profuse drooling)
Package insert 
study 17
Double-blind, 
placebo-
controlled
20 subjects with  
cerebral palsy, mental 
retardation, or other 
neurologic condition 
associated with problem 
drooling defined as 
drooling in the absence  
of treatment so that 
clothing became damp  
on most days 
(approximately  
5–7 days per week)
0.02 mg/kg/dose to  
0.1 mg/kg/dose tid,  
not exceeding  
3 mg tid
Up to 4 week titration  
plus 4 weeks at  
maximum tolerated  
dose
9-point modified Teacher 
Drooling Scale6 (0 = dry, 
never drools to 9 = profuse, 
clothing, hands, tray, and objects 
frequently become wet)
Study 27 Open-label 151 patients  
(20 patients from  
study 1 plus additional  
131 patients)
Not stated in package 
insert; per FDA  
Summary Review,18  
max 3 mg tid 
0.02 mg/kg, 0.04 mg/kg, 
0.06 mg/kg, 0.08 mg/kg, 
0.1 mg/kg
Not stated in package 
insert; per FDA  
Summary Review, 
24 weeks
Not stated in package insert; 
per FDA Summary Review,18 
9-point modified Teacher 
Drooling Scale
Abbreviations: FDA, Food and Drug Administration; tid, three times a day.
may have   clinical validity, and reviews of glycopyrrolate and 
drooling11–14 also discuss issues related to appropriate outcome 
measure for drooling intervention studies.
Open-label studies
Blasco and Stansbury15 report a prospective study of open-
label glycopyrrolate in 40 children and young adults who 
had either motor and/or cognitive difficulties associated with 
severe drooling. Dosing was initiated at 0.5 mg daily to twice 
daily. Patients were assessed every 5–10 days to ascertain 
response and side effects. The primary outcome measure was 
the subjective answer to the question, “is the drooling worse, 
better, or the same?” Of the 40 subjects, two had immedi-
ate allergic responses and of the remaining 38 subjects, 36 
reported drooling was improved. However, in no subject 
was glycopyrrolate successful for eliminating drooling. Nine Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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of 40 subjects (22.5%) discontinued glycopyrrolate due to 
side effects.
Stern16 conducted a small open-label trial of glycopyr-
rolate in 24 children and young adults with once daily dosing 
of glycopyrrolate. Dose titration was not specified, other than 
patients were initiated at 0.04 mg/kg/day and increased to 
0.1 mg/kg/day with a maximum of 0.175 mg/kg/day. The 
author states that “the majority of subjects show improve-
ment in both severity and frequency of drooling while 
  taking glycopyrrolate.” Details of statistical analyses do not 
include quantitation of improvements though the changes on 
glycopyrrolate were reported as highly significant for both 
frequency and severity. Side effects reported were relatively 
mild. From the discussion, it appears that three children 
(12.5%) discontinued the drug due to lack of effectiveness at 
lower dose rather than from glycopyrrolate side effects.
Bachrach et al first reported in abstract form,17 and subse-
quently in manuscript form,13 on their retrospective, open-label 
experience using glycopyrrolate in children with cerebral palsy. 
In their retrospective survey of 1437 patients, about one-third 
(34%) reported drooling sometimes and 16% reported drooling 
was often a problem. Of 54 patients for whom antisialorrheic 
medications were prescribed, the authors were able to obtain 
questionnaire data for 41 (76%). Of these 41 patients, most 
(37 patients, 90%) had used glycopyrrolate and almost half 
(46%) reported side effects, with almost a third (10/37, 27%) 
discontinuing glycopyrrolate due to side effects.
Another open-label study of 151 children is referred to in 
the package insert7 and the listing of side effects in the pack-
age insert are reportedly from both the placebo-controlled 
trial as well as the 24-week open-label extension, but no other 
details of methodology nor details of results are provided in 
the package insert. Some details are available from the FDA 
Summary Review and are included in Table 1.18
Double-blind studies
Two double-blind studies of glycopyrrolate were identified, 
only one of which has been published. Mier et al performed a 
double-blind dose-ranging study of glycopyrrolate in 39 children 
with developmental disabilities and “bothersome” drooling who 
were seen in pediatric hospital outpatient clinics.19 Most of the 
subjects in this report (34/39) had cerebral palsy. Dosing was 
determined by weight: for subjects less than 30 kg, dosing was 
initiated at 0.6 mg/dose three times daily and increased at weekly 
intervals to 1.2, 1.8, and 2.4 mg/dose. For subjects weighing 
more than 30 kg, initial dosing was 1.2 kg/dose three times daily 
and was increased as tolerated at weekly intervals to 1.8, 2.4, 
and 3.0 mg. Doses of 0.10 mg/kg per dose appeared effective 
at reducing sialorrhea as measured by parental/caregiver and 
investigator evaluation on a nine-point scale. However, even 
at low doses, 20% of children exhibited adverse events severe 
enough to warrant discontinuation of the medication.
Summary
For children with chronic neurological conditions, drooling 
may result from disturbances of saliva production, oral motor 
or sensory deficits, or diminished cognitive awareness. Chronic 
drooling is common, may be socially disabling, and may cause 
such secondary problems as dermatitis, skin maceration, or 
infection. Management options to help individuals with saliva 
control have included practicing oral motor exercises, using 
intraoral devices, prescribing anticholinergic medications, 
repeatedly injecting botulinum toxin in the salivary glands, 
and performing surgical interventions on the salivary glands. 
Of available anticholinergic medications, the synthetic anti-
cholinergic glycopyrrolate is appealing because of its’ poor 
central nervous system penetration and theoretically reduced 
likelihood of causing centrally-mediated side effects. 
However, remarkably few formal studies have explored 
the efficacy and safety of glycopyrrolate for sialorrhea in this 
population; only four clinical investigations of glycopyrrolate 
have been published and only one of these was double-blind. 
Except for the unpublished, open-label study referred to in 
the Cuvposa™ package insert, none of the studies included 
more than 40   subjects treated with glycopyrrolate.
While authors consistently report a positive response to 
glycopyrrolate, in three of the four studies over 20% of sub-
jects discontinued the medication due to side effects. Further-
more, constipation is consistently mentioned as a common 
side effect, with Bachrach et al noting a case of pseudo-
obstruction.13 Thus, for children with prior history of severe 
constipation or pseudoobstruction, clinicians may want to 
try other modalities before considering glycopyrrolate or 
other anticholinergic medications.
No s  tudies have compared the various anticholinergic 
medications head-  to-head, nor have studies compared 
medical and other   treatment modalities with each other 
prospectively. Clinicians are thus left to consider the relative 
severity each patient’s comorbidities and their own   clinical 
experience when considering and choosing management 
options for chronic drooling. It is not   surprising that with 
limited published data, surveys of clinicians treating patients 
with drooling have reported varying   prescribing patterns.13,20 
Scopolamine is reported the most common first-line therapy 
in the UK20 whereas glycopyrrolate is the most commonly 
used anticholinergic agent in the US.13
Clinicians trying to interpret the clinical data are also 
hampered because the available studies use different outcome Neuropsychiatric Disease and Treatment
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measures. While the scale described by Thomas-Stonell 
and Greenberg (Drooling Severity and Frequency Scale 
[DSFS])21 and the Teacher Drooling Scale22 (TDS) are easy 
to use, advocated for clinical practice,23 and had outcome 
measures evaluated in one or more of the studies listed in 
Table 1, neither has undergone rigorous clinimetric testing. 
The Drooling Impact Scale24 (DIS) has been developed as a 
validated, semiquantitative assessment of drooling that will 
also be responsive to interventions. Even with the high vari-
ability in clinical symptoms in this patient population, the DIS 
appears a reasonable semiquantitative, validated assessment 
scale appropriate for use as an outcome measure. However, 
the DIS has not yet been used in multiple studies of drooling. 
To allow comparisons to existing studies, future investigators 
may consider using the DIS along with such other outcome 
measures as DSFS, TDS, or practical assessments listed in 
Table 2 when trying to assess efficacy of an intervention.
Thus, while glycopyrrolate is available in both oral tablet 
and as a solution and is an option for treating patients with 
chronic drooling due to neurological conditions, caregivers 
should be advised that patients may not tolerate glycopyr-
rolate and the medication will help control, but not likely 
abolish pathological drooling.
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